Form 4 for LGND LIGAND PHARMACEUTICALS INC
Accepted 2023-08-14 00:00:00 ET · period of report 2023-08-10 · accession 0000886163-23-000051 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-08-14 | 2023-08-10 | LGND | Reardon Andrew | CLO | F - Tax | $68.73 | -897 | 15.4K | -6% | -$61.7K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-08-10 | F | D | 897 | $68.73 | 15,411 | D | — | — | (F1) Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of restricted stock units. |